ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Bafna Pharmaceuticals' 31st AGM held on September 11, 2026 approved adoption of audited financials, a director re-appointment, and cost auditor ratification. No specific monetary transaction was transacted.
Bafna Pharmaceuticals Limited has submitted its Annual Report for the financial year 2025-2026 and announced the date for its 31st Annual General Meeting.
Bafna Pharmaceuticals Limited will hold its 31st Annual General Meeting on September 11, 2026. The book closure is scheduled from September 05 to September 11, 2026.
Bafna Pharmaceuticals Ltd reported revenue from operations of ₹26.6 Cr (-23.1% YoY) and net profit of ₹0.1 Cr (-97.1% YoY) for Q1 FY27.
Bafna Pharmaceuticals has scheduled a board meeting for August 11, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Bafna Pharmaceuticals has filed its quarterly shareholding pattern as of June 30, 2026, in compliance with SEBI LODR regulations.
Bafna Pharmaceuticals Ltd reported revenue from operations of ₹42.2 Cr (+7.9% YoY) and net profit of ₹2.7 Cr (+107.7% YoY) for Q4 FY26.
Bafna Pharmaceuticals reported audited financial results for the year ended March 31, 2026. The filing includes the Balance Sheet, Cash Flow, and an unmodified auditor's report.
Bafna Pharmaceuticals scheduled a board meeting for May 29, 2026, to approve audited financial results. The trading window remains closed until May 31, 2026.
Bafna Pharmaceuticals Ltd clarified to stock exchanges that recent significant share price movements are market-driven and attributable to general market conditions. The company confirmed it has not withheld any price-sensitive information and remains compliant with all SEBI disclosure regulations. Management stated they have no connection with or control over the share price movement.